Format

Send to

Choose Destination
Cancer Radiother. 2014 Oct;18(5-6):391-5. doi: 10.1016/j.canrad.2014.06.012. Epub 2014 Aug 30.

Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives.

Author information

1
Department of radiation oncology (MaastRO Lab), GROW - School for oncology and developmental biology, Maastricht university medical center, UNS 50/23, PO Box 616, 6200 MD Maastricht, The Netherlands. Electronic address: nicolle.rekers@maastrichtuniversity.nl.
2
Department of radiation oncology (MaastRO Lab), GROW - School for oncology and developmental biology, Maastricht university medical center, UNS 50/23, PO Box 616, 6200 MD Maastricht, The Netherlands.
3
Department of internal medicine, GROW - School for oncology and developmental biology, Maastricht university medical centre, UNS 50/23, PO Box 616, 6200 MD Maastricht, The Netherlands.

Abstract

Radiotherapy is along with surgery and chemotherapy one of the prime treatment modalities in cancer. It is applied in the primary, neoadjuvant as well as the adjuvant setting. Radiation techniques have rapidly evolved during the past decade enabling the delivery of high radiation doses, reducing side-effects in tumour-adjacent normal tissues. While increasing local tumour control, current and future efforts ought to deal with microscopic disease at a distance of the primary tumour, ultimately responsible for disease-progression. This review explores the possibility of bimodal treatment combining radiotherapy with immunotherapy.

KEYWORDS:

Immunotherapy; Immunothérapie; Radiothérapie stéréotaxique ablative; Stereotactic ablative body radiotherapy

PMID:
25179250
DOI:
10.1016/j.canrad.2014.06.012
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center